ADAGIO THERAPEUTICS INC (ADGI) Forecast, Price Target & Analyst Ratings
NASDAQ:ADGI • US00534A1025
4.64 USD
+0.04 (+0.87%)
At close: Sep 12, 2022
4.52 USD
-0.12 (-2.59%)
After Hours: 9/12/2022, 8:13:11 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ADAGIO THERAPEUTICS INC (ADGI).
Forecast Snapshot
Consensus Price Target
$3.91
-15.73% Downside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2022
EPS Estimate-$0.50
Revenue Estimate
ChartMill Buy Consensus
46.67%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.91
Upside
-15.73%
From current price of $4.64 to mean target of $3.91, Based on 9 analyst forecasts
Low
$3.03
Median
$3.57
High
$5.25
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
9 analysts have analysed ADGI and the average price target is 3.91 USD. This implies a price decrease of -15.73% is expected in the next year compared to the current price of 4.64.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
46.67%
ADGI was analyzed by 9 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about ADGI.
In the previous month the buy percentage consensus was at a similar level.
ADGI was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-05-17 | Morgan Stanley | Maintains | Underweight |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-12-22 | Jefferies | Downgrade | Buy -> Hold |
| 2021-12-15 | Guggenheim | Downgrade | Buy -> Neutral |
| 2021-12-15 | Stifel | Downgrade | Buy -> Hold |
| 2021-12-15 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-11-29 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2021-08-31 | Guggenheim | Initiate | Buy |
| 2021-08-31 | Stifel | Initiate | Buy |
| 2021-08-31 | Morgan Stanley | Initiate | Equal-Weight |
| 2021-08-31 | Jefferies | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2022
EPS Estimate-$0.50
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q48.65%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 1,233.34% | N/A 145.10% | N/A 150.00% | |||
| EBITDA YoY % growth | N/A | -226.907M | N/A 3.35% | N/A 2.33% | N/A 56.26% | N/A -26.76% | N/A -29.29% | |
| EBIT YoY % growth | -65.327M | -226.908M -247.34% | N/A -12.80% | N/A 8.82% | N/A 36.34% | N/A -20.18% | N/A -22.58% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A -2.35% | N/A 17.36% | N/A 30.42% | N/A -21.46% | N/A -23.89% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 22 | Q4 / 22 | |
|---|---|---|
| EPS Q2Q % growth | -0.50 48.65% | -0.53 31.56% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -55.225M 8.60% | -57.568M 30.72% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
12.17%
EPS Next 5 Year
2.19%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ADAGIO THERAPEUTICS INC / ADGI Forecast FAQ
What do analysts expect the price target to be for ADAGIO THERAPEUTICS INC (ADGI)?
9 analysts have analysed ADGI and the average price target is 3.91 USD. This implies a price decrease of -15.73% is expected in the next year compared to the current price of 4.64.
What are the consensus estimates for ADGI stock next earnings?
The consensus EPS estimate for the next earnings of ADAGIO THERAPEUTICS INC (ADGI) is -0.5 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for ADAGIO THERAPEUTICS INC stock?
The consensus rating for ADAGIO THERAPEUTICS INC (ADGI) is 46.6667 / 100 . This indicates that analysts generally have a neutral outlook on the stock.